Molecular imaging used to differentiate cerebral amyloid angiopathy and Alzheimer’s disease


  • [18F]FDG positron emission tomography (PET)/computed tomography (CT) may have diagnostic utility in differentiating cerebral amyloid angiopathy (CAA) in general and preclinical Alzheimer’s disease (AD), in particular in patients with positive amyloid PET.

Why this matters

  • CAA is increasingly encountered in daily neurological routine, but a definite CAA diagnosis requires a full post-mortem analysis.

  • A similar recent study was conducted using early-phase 11C-labelled Pittsburgh compound B PET to distinguish probable CAA and AD, based on known histopathological and imaging topographic differences between these two disorders.

  • However, amyloid PET is not widely available, so this study sought a more clinically available alternative.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.